Chemoinformaics analysis of ENT-KAUR-16-EN-19-OIC-ACID
| Molecular Weight | 234.339 | nRot | 2 |
| Heavy Atom Molecular Weight | 212.163 | nRig | 14 |
| Exact Molecular Weight | 234.162 | nRing | 5 |
| Solubility: LogS | -3.376 | nHRing | 0 |
| Solubility: LogP | 2.532 | No. of Aliphatic Rings | 5 |
| Acid Count | 1 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 5 |
| Atoms Count | 39 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 17 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 6 | No. Saturated Carbocycles | 5 |
| No. of Hydrogen atom | 22 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 5 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 41.3234 |
| nHD | 1 | BPOL | 22.9386 |
| QED | 0.797 |
| Synth | 5.994 |
| Natural Product Likeliness | 2.615 |
| NR-PPAR-gamma | 0.008 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0 |
| Pgp-sub | 0 |
| HIA | 0.007 |
| CACO-2 | -5.007 |
| MDCK | 0.000110856 |
| BBB | 0.967 |
| PPB | 0.917077 |
| VDSS | 0.528 |
| FU | 0.0636498 |
| CYP1A2-inh | 0.039 |
| CYP1A2-sub | 0.763 |
| CYP2c19-inh | 0.015 |
| CYP2c19-sub | 0.933 |
| CYP2c9-inh | 0.04 |
| CYP2c9-sub | 0.817 |
| CYP2d6-inh | 0.004 |
| CYP2d6-sub | 0.236 |
| CYP3a4-inh | 0.019 |
| CYP3a4-sub | 0.191 |
| CL | 17.747 |
| T12 | 0.299 |
| hERG | 0.016 |
| Ames | 0.003 |
| ROA | 0.576 |
| SkinSen | 0.062 |
| Carcinogencity | 0.111 |
| EI | 0.018 |
| Respiratory | 0.864 |
| NR-Aromatase | 0.003 |
| Antiviral | Yes |
| Prediction | 0.818321 |